Oncoceutics

  •  

    Case Report in the Journal of Neurosurgery Highlights Potential of ONC201 in H3 K27M-mutant DIPG

    Last fall, we announced our collaboration with Musella Foundation, xCures, The Cure Starts Now Foundation, Michael Mosier Defeat DIPG Foundation, and Oncoceutics to help patients access ONC201, a new, experimental treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M. Oncoceutics now reports the publication of a case study of a 10-year-old patient for whom ONC201… Read more »

  •  

    xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

    LOS ALTOS, Calif., March 12, 2019 /PRNewswire/ — xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled “ONC018: Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas” that… Read more »

  •  

    Promising Developments for Brain Tumor Drug ONC201

    In September, we announced our collaboration with Musella Foundation, xCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M. Since then, several news stories have reported promising developments for ONC201. Check out the coverage: The Philadelphia Inquirer: “Cancer therapy shows promise for… Read more »

  •  

    Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas

    Musella Foundation, Cancer Commons, xCures and Oncoceutics announced the initiation of a collaboration to develop ONC201 as a new treatment for diffuse intrinsic pontine glioma (DIPG) and other H3 K27M-mutant gliomas. Critical to the collaboration is $1M in funding from The Musella Foundation, Michael Mosier Defeat DIPG Foundation and The Cure Starts Now Foundation. Cancer Commons and xCures will contribute additional resources to the… Read more »